Telenzepine

Drug Profile

Telenzepine

Alternative Names: BY 803; BY 80832; SK 871

Latest Information Update: 24 Jun 2002

Price : $50

At a glance

  • Originator ALTANA Pharma
  • Developer ALTANA Pharma; Sanwa Kagaku Kenkyusho
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Muscarinic M1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Peptic ulcer

Most Recent Events

  • 24 Jun 2002 Discontinued - Phase-III for Peptic ulcer in Japan (PO)
  • 24 Jun 2002 Discontinued - Preregistration for Peptic ulcer in Germany (PO)
  • 24 Jun 2002 Discontinued - Clinical-Phase-Unknown for Asthma (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top